- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03736044
Reconstitution of CD4+CD25highCD127low/-Tcell
Analysis of T Cell Population to Obtain a Free-drug Remission in Patients Affected by Rheumatoid Athritis in Remission Phase Induced by TNF-blocker Therapy
Rheumatoid arthritis (RA) is a systemic disabling inflammatory disease, of autoimmune origin characterized by chronic synovial inflammation resulting in joint damage. Treg cell function in patients with active RA is assumed to be impaired, a trend that seems to be reversed by TNFalpha antagonist therapy. Remission is the current treatment goal in RA.
An increasing number of patients in clinical trials achieve this goal raising the question whether patients who have been in remission for a prolonged period (sustained remission) still need medication indefinitely. From a decade TNF-blocker therapy have represented a new treatment option for RA patients non responders to conventional DMARDs and some evidence are now available showing that sustainable remission can be maintained achieved after withdrawal of TNF blocker. Objectives: to verify whether in RA patients in prolonged clinical and instrumental remission the percentages of CD4+CD25highCD127low/- T cells could represent a reliable marker of immunological remission and, even more relevant, if the pharmacological reconstitution of this "immune-modulator" Tcell population could contribute to better identify patients with a low risk of relapse after cessation of TNF-blocker therapy. Methods: in RA patients, who fulfilled the 1987 ACR revised criteria, with disease duration ! 5 years, clinical [Disease Activity Score on 28 joints-DAS28 0.56 ×√(TJC28) + 0.28×√(SJC28) + 0.70×ln(ESR) + 0.014×GH.TJC= Tender Joints Count (from 0 to 28); SJC= Swollen Joints Count (from 0 to 28) ESR=Erythrocyte Sedimentation Rate GH= patient's assessment of general health (VAS range from 0 to 100 mm); disease's flare was considered if: DAS44 >=2.4/DAS28 >=3.2.)], instrumental (joint ultrasonography: sites to be explored wrists are II-III metacarpophalangeal joint bilaterally using Power Doppler signal (grading 0-3); any other joint will be studied if symptomatic) and immunological (circulating CD4+CD25highCD127low/-Tcells and inflammatory cytokines levels) examination will be performed in order to asses, at different levels, disease activity status. Expected results: to identify in RA patients treated with anti-TNF an "exit-strategy" from these drugs based on clinical, imaging and immunologic features indicative of a sustained remission and to verify whether such conditions are able to predict a low incidence of relapse.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- To evaluate the incidence of disease flare after cessation of anti-TNF therapy in patients that meet sustained clinical and instrumental remission criteria together with reconstitution of the CD4+CD25highCD127low/- Tcell population respect to those patients in the same remission status with persistent low CD4+CD25highCD127low/- Tcell population.
- Assessment of CD4+CD25highCD127low/- Tcell population behaviour induced by different drug treatments (anti-TNF vs DMARDs) in patient with RA who have achieved a prolonged remission status.
- To assess the predictive value of modifications of CD4+CD25highCD127low/- Tcell population in patients who relapse.
Study design: all RA patients satisfying inclusion criteria will undergo to a baseline clinical, instrumental and immunologic evaluation. Peripheral CD4+CD25highCD127low/- Tcell population will be checked for and patients will be stratified in 2 groups:
- Group A: patients on treatment with TNF-blockers plus DMARDs
- Group B: patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF In addition a cohort of healthy subjects matched for sex and age will be used as a control.
Patient's blood samples will be centralized at the "Laboratories of Technology for Advanced Therapies" of the University of Ferrara (www.ltta.tecnopoloferrara.it) directed by Prof. Paola Secchiero.
In group A anti-TNF drugs will be withdrawn and patients will be followed up. Patients belonging to the group B will be followed up without any further intervention. A tight clinical monitoring will be instituted and disease flares-up will be recorded. In case of disease flare therapeutic adjustment will be provided to the patients by the attending specialist team accordingly to the current standard of care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with RA fulfilling the 1987 ACR classification criteria (10) treated with anti-TNF and/or conventional DMARDs for at least 12 months, in prolonged remission (DAS28 <2.6 or DAS44 <1.6) for at least 6 months (checked in two consecutive visits 3 months apart), without Glucocorticosteroid (for at least 3 months, before), on a stable treatment for at least 3 months.
Exclusion Criteria:
- assumption of glucocorticosteroids within the three months before; confounding comorbidities such as fibromyalgia; chronic inflammatory disease other than RA; ongoing infections at the time of enrolment; recent trauma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TNF-blockers withdrawal
Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
|
in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
|
No Intervention: DMARDs control group
Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects who flare-up after cessation of anti-TNF therapy after 24 months
Time Frame: 24 months
|
disease flare-up defined as DAS 28 >3.2
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects who are still in remission or il low disease activity after 3, 6, 9, 12, 15, 18, 21, 24 months
Time Frame: 24 months
|
disease remission/low disease activity defined as DAS 28 <=3.2
|
24 months
|
Swollen joint counts after 3, 6, 9, 12, 15, 18, 21, 24 months
Time Frame: 24 months
|
Number of Swollen Joints (range from 0 to 28) at clinical examination
|
24 months
|
Tender joint counts after 3, 6, 9, 12, 15, 18, 21, 24 months
Time Frame: 24 months
|
Number of Tender joints (range from 0 to 28) at clinical examination
|
24 months
|
Patient self assessment of pain (VAS) after 3, 6, 9, 12, 15, 18, 21, 24 months
Time Frame: 24 months
|
Severity of pain measured by visual analogic scale (0-10)
|
24 months
|
Physician's and patient's assessment of global disease activity (VAS) after 3, 6, 9, 12, 15, 18, 21, 24 months
Time Frame: 24 months
|
Physician and Patient evaluation of Global disease activity measured by visual analogic scale (0-100)
|
24 months
|
HAQ (Health Assessment Questionnaire) after 3, 6, 9, 12, 15, 18, 21, 24 months
Time Frame: 24 months
|
Evaluation of disability by HAQ.
There are 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities.
There are 2 or 3 questions for each section.
Scoring within each section is from 0 (without any difficulty) to 3 (unable to do).The 8 scores of the 8 sections are summed and divided by 8.
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRUa1GR-2013 -00000156
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on TNF-blockers suspension in patients with rheumatoid arthritis
-
University Hospital Center of MartiniqueCompletedStudy of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis (HLAPRPA)Rheumatoid ArthritisMartinique
-
Weill Medical College of Cornell UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)RecruitingCardiovascular Diseases | Rheumatoid Arthritis | HyperlipidemiasUnited States
-
Centre Hospitalier Universitaire de Saint EtienneTerminated
-
Instituto Nacional de Cardiologia Ignacio ChavezRecruitingRheumatoid Arthritis | Inflammatory Response | Diet, HealthyMexico
-
Shinshu UniversityShowa Inan General HospitalRecruiting
-
Changi General HospitalSingapore General HospitalRecruitingPrimary Aldosteronism | Hypokalemia | Chronic Renal Disease | Cardiovascular Morbidity | Mineralocorticoid Excess | Adrenalectomy; Status | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) | Mineralocorticoid Antagonists [Aldosterone...Singapore
-
Sohag UniversityNot yet recruiting
-
Hanoi Medical UniversityCompletedAnalgesia | Spine FusionVietnam
-
Aligos TherapeuticsRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed